Trump Administration Files Patent Infringement Lawsuit Against Gilead Over HIV PrEP Drugs

New York Times: Trump Administration Sues Gilead, Maker of HIV-Prevention Drugs
“The Trump administration on Wednesday sued Gilead Sciences, a pharmaceutical company that sells HIV-prevention drugs that can cost patients up to $20,000 a year [in the U.S.], accusing the company of earning billions from research funded by taxpayers without paying taxpayers back. The government said the company infringed upon patents owned by the Department of Health and Human Services, and had refused attempts by the department to license its patents and collect royalties. The company sells two drugs, Truvada and Descovy, that can be taken once daily to prevent HIV infection, a strategy called pre-exposure prophylaxis, or PrEP…” (Victor, 11/7).

Additional coverage of the lawsuit is available from Daily Beast, HuffPost, and Washington Post.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.